Page 250 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

224 Loic Guillevin

[82] Cruz BA, Ramanoelina J, Mahr A, et al. Prognosis and outcome of 26 patients with
systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology 2003;
42:1183-1188.

[83] Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score
(BVAS) in systemic necrotizing vasculitis. QJM 1994; 87):671-678.

[84] Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and
Churg–Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75:17-
28.

[85] Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic
vasculitis and is an index of outcome. QJM 1997; 90:391-399.

[86] Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic
necrotizing vasculitis. N. Engl. J. Med. 1979; 301:235-238.

[87] Guillevin L. [How to treat systemic necrotizing vasculitides?]. Presse Med. 2012;
41:1024-30.

[88] Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse
events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.
Arthritis. Rheum. 2011; 63:1435-1445.

[89] Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis
nodosa and Churg–Strauss syndrome: comparison of steroids and oral or pulse
cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br
J. Rheumatol. 1997; 36:1290-1297.

[90] Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy
for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J.
Med. 2003; 349:36-44.

[91] Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance
for ANCA-associated vasculitis. N. Engl. J. Med. 2008; 359:2790-2803.

[92] Généreau T, Lortholary O, Leclerq P, et al. Treatment of systemic vasculitis with
cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration
after failure of a pulse intravenous high-dose regimen in four patients. Br. J. Rheumatol.
1994; 33:959-962.

[93] Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic
polyangiitis without poor-prognosis factors: a prospective randomized study of one
hundred twenty-four patients. Arthritis. Rheum. 2010; 62:1186-1197.

[94] Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma
exchange to steroids alone in the treatment of polyarteritis nodosa and Churg–Strauss
syndrome. A prospective, randomized trial in 78 patients. Arthritis. Rheum. 1992;
35:208-215.

[95] Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and
plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the
treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors
predicting poor prognosis. A prospective, randomized trial in sixty-two patients.
Arthritis. Rheum. 1995; 38:1638-1645.

[96] Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to
hepatitis B virus with interferon-alpha and plasma exchanges. Ann. Rheum. Dis. 1994;
53:334-337.

Complimentary Contributor Copy